NCT01638676View on ClinicalTrials.gov

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2027

Conditions
Melanoma
Interventions
DRUG

Vemurafenib

Vemurafenib (960 mg PO daily) in patients with unresectable BRAFV600E positive Stage IIIC and Stage IV melanoma

DRUG

Metformin

Metformin (500 mg PO BID x 2 weeks, then 850 mg PO BID)

Trial Locations (1)

40202

RECRUITING

James Graham Brown Cancer Center-University of Louisville, Louisville

All Listed Sponsors
collaborator

James Graham Brown Cancer Center

OTHER

lead

University of Louisville

OTHER

NCT01638676 - A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients | Biotech Hunter | Biotech Hunter